- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
- 8-K Current report
- 3.1 EX-3.1
- 3.2 EX-3.2
- 3.3 EX-3.3
- 10.2 EX-10.2
- 10.3 EX-10.3
- 10.4 EX-10.4
- 10.5 EX-10.5
- 10.7 EX-10.7
- 10.8 EX-10.8
- 10.9 EX-10.9
- 10.10 EX-10.10
- 23.1 EX-23.1
- 99.1 Tourmaline Bio Announces Closing of Merger with Talaris Therapeutics and Concurrent Private Placement of $75 Million
- Download Excel data file
- View Excel data file
- 30 Nov 23 Departure of Directors or Certain Officers
- 14 Nov 23 Index to Unaudited Condensed Financial Statements
- 27 Oct 23 Departure of Directors or Certain Officers
- 19 Oct 23 Tourmaline Bio Announces Closing of Merger with Talaris Therapeutics and Concurrent Private Placement of $75 Million
- 17 Oct 23 Talaris Therapeutics Announces Stockholder Approval of Merger with Tourmaline Bio
- 10 Oct 23 Other Events
- 6 Oct 23 Talaris Therapeutics Declares Special Dividend
Exhibit 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We consent to the incorporation by reference in Registration Statement No. 333-266875 on Form S-3 and Registration Statements Nos. 333-255835, 333-263647, and 333-271033 on Forms S-8, of Tourmaline Bio, Inc. (formerly, Talaris Therapeutics, Inc.) of our report dated June 9, 2023, relating to the financial statements of Tourmaline Bio, Inc. (now known as Tourmaline Sub, Inc.) appearing in the definitive proxy statement filed by Talaris Therapeutics, Inc. with the Securities and Exchange Commission on September 15, 2023, which is incorporated by reference in this Current Report on Form 8-K dated October 19, 2023.
/s/ Deloitte & Touche LLP |
Morristown, New Jersey |
October 19, 2023 |